We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
-2.2%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$78.1B
AUM Growth
-$1.98B
(-2.5%)
Cap. Flow
-$7.02B
Cap. Flow
% of AUM
-8.99%
Top 10 Holdings %
Top 10 Hldgs %
28.7%
Holding
1,440
New
63
Increased
853
Reduced
452
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kinross Gold
KGC
|
+$440M |
| 2 |
C.H. Robinson
CHRW
|
+$323M |
| 3 |
Advanced Micro Devices
AMD
|
+$322M |
| 4 |
Tyler Technologies
TYL
|
+$317M |
| 5 |
Merck
MRK
|
+$286M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$11.9B |
| 2 |
NVIDIA
NVDA
|
+$409M |
| 3 |
Autodesk
ADSK
|
+$261M |
| 4 |
Salesforce
CRM
|
+$258M |
| 5 |
Clorox
CLX
|
+$238M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 40.82% |
| 2 | Materials | 22.17% |
| 3 | Healthcare | 8.64% |
| 4 | Industrials | 7.37% |
| 5 | Financials | 5.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
CAVA Group
CAVA
$7.51B
| $139K | ﹤0.01% |
1,232
-452
| -27% | -$60.3K |
|
|
STKL
1252
DELISTED
SunOpta
STKL
| $139K | ﹤0.01% |
18,070
+7,097
| +65% | +$50.2K |
|
1253
Playtika
PLTK
$1.54B
| $138K | ﹤0.01% |
19,913
-1,469
| -7% | -$11.6K |
|
1254
SITE Centers
SITC
$174M
| $138K | ﹤0.01% |
8,996
-32,856
| -79% | -$530K |
|
1255
VTEX
VTEX
$750M
| $137K | ﹤0.01% |
23,262
+75
| +0.3% | +$492 |
|
|
INN
1256
Summit Hotel Properties
INN
$749M
| $136K | ﹤0.01% |
19,879
+1,842
| +10% | +$12.1K |
|
1257
Perion Network
PERI
$382M
| $135K | ﹤0.01% |
15,976
-825
| -5% | -$6.93K |
|
1258
Colgate-Palmolive
CL
$71.6B
| $133K | ﹤0.01% |
1,466
-35,344
| -96% | -$3.37M |
|
1259
Integer Holdings
ITGR
$4.23B
| $131K | ﹤0.01% |
987
-60
| -6% | -$8K |
|
1260
Envista
NVST
$4.45B
| $128K | ﹤0.01% |
6,636
-236
| -3% | -$4.67K |
|
1261
Equitable Holdings
EQH
$13.1B
| $127K | ﹤0.01% |
2,692
-142
| -5% | -$6.56K |
|
1262
Doximity
DOCS
$3.95B
| $126K | ﹤0.01% |
2,352
+388
| +20% | +$19K |
|
1263
Transmedics
TMDX
$2.82B
| $125K | ﹤0.01% |
1,997
+1,010
| +102% | +$94K |
|
1264
Ituran Location and Control
ITRN
$1.1B
| $121K | ﹤0.01% |
3,871
+392
| +11% | +$11.1K |
|
1265
RxSight
RXST
$260M
| $112K | ﹤0.01% |
3,265
+1,040
| +47% | +$46.9K |
|
|
AZPN
1266
DELISTED
Aspen Technology Inc
AZPN
| $111K | ﹤0.01% |
443
-255
| -37% | -$62.2K |
|
|
AZUL
1267
DELISTED
Azul
AZUL
| $106K | ﹤0.01% |
63,338
+8,899
| +16% | +$23.2K |
|
|
ALTR
1268
DELISTED
Altair Engineering Inc
ALTR
| $101K | ﹤0.01% |
926
-432
| -32% | -$44.6K |
|
1269
Corebridge Financial
CRBG
$14B
| $100K | ﹤0.01% |
3,325
+805
| +32% | +$24.8K |
|
1270
Novanta
NOVT
$5.28B
| $99K | ﹤0.01% |
649
-314
| -33% | -$53.2K |
|
1271
Alphatec Holdings
ATEC
$1.56B
| $98K | ﹤0.01% |
10,722
-8,551
| -44% | -$68.3K |
|
|
BPMC
1272
DELISTED
Blueprint Medicines
BPMC
| $97K | ﹤0.01% |
1,116
+363
| +48% | +$33.3K |
|
1273
Dr. Reddy's Laboratories
RDY
$10.1B
| $92K | ﹤0.01% |
5,838
+1,723
| +42% | +$25.9K |
|
1274
Vitamin Cottage Natural Grocers
NGVC
$765M
| $91K | ﹤0.01% |
2,301
+575
| +33% | +$19.9K |
|
1275
Fox Class A
FOXA
$24.6B
| $89K | ﹤0.01% |
+1,838
| New | +$82.8K |
|
Similar funds
VanEck Associates's Q4 2024 Portfolio in Review
As of Q4 2024, VanEck Associates held 1,440 positions worth $78.1B, down 2.5% from $80.1B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
VanEck Associates withdrew a net $7.02B in Q4 2024, closing 54 positions and reducing 452 holdings. Its most notable exit was Bank of New York Mellon, an estimated $9.49M position sold in full.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 41% a quarter earlier, followed by Materials and Healthcare.
Against the trend, VanEck Associates opened a new position in Boeing Co 6.00% Series A Preferred Stock worth $251M.
- VanEck Associates's largest Q4 2024 buy was Boeing Co 6.00% Series A Preferred Stock: 4,123,397 shares worth $251M.
- VanEck Associates added most to Kinross Gold in Q4 2024, an estimated $440M increase.
- VanEck Associates's biggest Q4 2024 reduction was Lam Research, cutting an estimated $11.9B.
- VanEck Associates fully exited Bank of New York Mellon in Q4 2024, selling an estimated $9.49M.
- VanEck Associates's ten largest holdings make up 29% of its $78.1B portfolio in Q4 2024.
- VanEck Associates opened 63 new positions and closed 54 in Q4 2024.
- VanEck Associates's portfolio value fell 2.5% quarter-over-quarter to $78.1B.
Based on VanEck Associates's 13F filing for Q4 2024, filed 29 Jan 2025.